Annotation Detail

Information
Associated Genes
GNAS
Associated Variants
GNAS p.Leu131= (p.L131=) ( ENST00000306090.12, ENST00000306120.4, ENST00000313949.11, ENST00000349036.9, ENST00000371075.7, ENST00000371098.6, ENST00000371100.9, ENST00000371102.8, ENST00000419558.7, ENST00000423897.7, ENST00000453292.7, ENST00000462499.6, ENST00000467227.6, ENST00000472183.6, ENST00000482112.6, ENST00000491348.5, ENST00000493744.5, ENST00000657090.1, ENST00000663479.2, ENST00000676826.2 )
GNAS p.Leu131= (p.L131=) ( ENST00000306090.12, ENST00000306120.4, ENST00000313949.11, ENST00000349036.9, ENST00000371075.7, ENST00000371098.6, ENST00000371100.9, ENST00000371102.8, ENST00000419558.7, ENST00000423897.7, ENST00000453292.7, ENST00000462499.6, ENST00000467227.6, ENST00000472183.6, ENST00000482112.6, ENST00000491348.5, ENST00000493744.5, ENST00000657090.1, ENST00000663479.2, ENST00000676826.2 )
Associated Disease
esophageal cancer
Source Database
CIViC Evidence
Description
Overall, 63% of the patients in the T-allele group (TT + CT), i.e with the T393C genotype, were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) genotypes (CC) showed a major histopathological response with less than 10% residual vital tumor cells in 80%.
Variant Origin
Common Germline
Variant Origin
Common Germline
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/2895
Gene URL
https://civic.genome.wustl.edu/links/genes/2319
Variant URL
https://civic.genome.wustl.edu/links/variants/877
Rating
4
Evidence Type
Predictive
Disease
Esophageal Cancer
Evidence Direction
Supports
Drug
Cisplatin,Fluorouracil
Evidence Level
B
Clinical Significance
Resistance
Pubmed
19274060
Drugs
Drug NameSensitivitySupported
CisplatinResitance or Non-Reponsetrue
FluorouracilResitance or Non-Reponsetrue